The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Fulvestrant (F) plus sorafenib (S) as salvage therapy for hormone receptor positive (HR+) metastatic breast cancer (MBC) failing prior aromatase inhibitor (AI) treatment.
Kristine H. Lethert
No relevant relationships to disclose
Deirdre J. Nauman
No relevant relationships to disclose
Yolanda Prado
No relevant relationships to disclose
Mark Seligman
No relevant relationships to disclose
Kasra Karamlou
No relevant relationships to disclose
Frederick S. Ey
No relevant relationships to disclose
Stephen Y. Chui
No relevant relationships to disclose